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Background: Ganoderma lucidum polysaccharides (GLPS) have been used as traditional Chinese medicine for their
properties of cancer prevention and immunomodulation. However, it is unclear whether GLPS has therapeutic
effect on anti-hepatocellular carcinoma (HCC) in vivo. In this study, the effect of GLPS and their impact on the balance
of regulatory T cell (Treg) and effector T cell (Teff) was measured in a model of hepatoma-bearing mice.
Methods: The effect of GLPS and their impact on the balance of regulatory T cell (Treg) and effector T cell (Teff) were
measured in a model of hepatoma-bearing mice. Real-time PCR detected the levels of MicroRNAs (miRNAs) and mRNA.
The effects of Tregs on Teff proliferation were determined via suppression assay. The mircroRNA-125b (miR-125b)
inhibitor was used to down-regulate miR-125b expression.
Results: GLPS significantly suppressed tumor growth in hepatoma-bearing mice associated with an increase of
the ratio of Teffs to Tregs. Moreover, GLPS eliminate Treg suppression of Teff proliferation with an increase in IL-2
secretion. Addition of GLPS to treat T cells inhibited Notch1 and FoxP3 expression through increase of miR-125b
expression. In hepatoma-bearing mice, miR-125b inhibitor obviously abolished the effect of GLPS on tumor
growth.
Conclusions: This finding provides the novel evidence for GLPS on inhibition of HCC through miR-125b inhibiting
Tregs accumulation and function.
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Hepatocellular carcinoma (HCC) is one of the most lethal
cancers worldwide, especially in China [1]. Due to chronic
hepatitis infection and inflammation, the efficacy of che-
moembolization or systemic therapies on HCC remains
limited. Many researchers have found that CD4 +CD25+
regulatory T cells (Tregs) population increased in both the
peripheral blood and tumor microenvironment in HCC
patients, which correlates with a poor prognosis [2,3].
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unless otherwise stated.response and helping tumor cells to escape from immune
surveillance [4]. Therefore, targeting the number and
function of Tregs may be a useful and effective tool for
HCC therapies.
MicroRNAs (miRNAs) are small non-coding RNAs
involved in modulating gene expression at the post-
transcriptional level [5]. miRNAs play critical roles in
several different physiological processes, such as cell
proliferation, apoptosis, development, metabolism and
differentiation [6]. Increasing amounts of evidence have
demonstrated that alteration of miRNAs expression is
directly implicated in the process of tumorigenesis.
Some miRNAs acted as tumor suppressors and others
exerted an oncogenic activity [7,8]. Among these miRNAs,
miR-125b aberrant expression is involved in tumorigenesisis an Open Access article distributed under the terms of the Creative Commons
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miR-125b is significantly downregulated and exerts
tumor-suppressive function [10]. Jia et al. showed that
miR-125b expression was obviously decreased in HCC tis-
sues and cells, which is the prediction of aggressiveness
and poor prognosis of HCC [11].
Ganoderma lucidum, a traditional remedy, has been
widely used as adjuvant of anti-tumor therapy in clinic
[12]. Polysaccharides, one of the major categories of the
bioactive ingredients of ganoderma lucidum, have the
multiple biological activities such as improvement of
host immune function, prevention of oxidative damage,
protection of liver with little toxicity [13,14]. Recently,
the inhibitory effect of Ganoderma lucidum polysaccha-
rides (GLPS) on tumor has received great attention
[15,16]. GLPS could inhibit the tumor growth and im-
prove the immune function in vitro and in vivo [17].
The immune-modulating activities of GLPS were due to
different mechanisms, such as enhancing the cytotoxic
activity of NK cells, activating Dendritic cells (DCs), and
promoting T helper 1 immune responses [18]. However,
the molecular mechanism of GLPS on Tregs in HCC is
not clear. Therefore, in the present study, we have inves-
tigated the effect of GLPS on anti-hepatocellular carcin-
oma in vitro and in vivo, and explored the underlying
mechanisms associated with this activity.Method and material
Ethics statement
Animals were treated humanely, using approved proce-
dures in accordance with the guidelines of the Institu-
tional Animal Care and Use Committee at Nanjing
University. The study was approved by the Experimental
Animal Ethics Committee at Nanjing University.
Chemicals and reagents
RPMI 1640 and DMEM were obtained from GIBCO
(Invitrogen Company). Fetal bovine serum (FBS) was
from Hyclone (Logan, UT, USA). GLPS was purchased
from Johnsun Mushroom (Hangzhou, China). PHA and
MTT were purchased from Sigma Aldrich (St. Louis,
MO, USA). Lipofectamine 2000 transfection reagent was
obtained from Invitrogen Life Technologies (Grand
Island, NY, USA). Anti-mouse CD4-fluorescein isothio-
cyanate (FITC) and anti-mouse CD25-phycoeritrin (PE)
were obtained from eBioscience (San Diego, CA, USA).
Rabbit-anti-β-catenin and rabbit anti-Notch1 were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The Detergent Compatible (DC) Protein Assay kit
was purchased from Bio-Rad Laboratories (Hercules,
CA, USA). The miRNeasy Mini kit, the miScript Reverse
Transcription kit and the miScript SYBR Green PCR kit
were purchased from Qiagen (Hilden, Germany).Cell culture
The mouse hepatoma H22 cell line (syngenic to the
Kunming strain of mice) and normal hepatic cell line L-
02 were obtained from Chinese Academy of Sciences
(Shanghai, China). H22 cells were cultured in complete
RPMI 1640, and then 0.5 × 107 cells (200 μL) were
injected into the abdominal cavity of mouse. Seven days
later, the intraperitoneal tumor cells were collected from
the mouse with ascites tumor. L-02 cells were cultured
in DMEM, supplemented with 10% FBS maintained at
37°C in a humidified incubator containing 5% CO2.
Cultured cells were treated with GLPS (dissolved in
PBS) in complete medium.
Hepatoma-bearing mice
Kunming and BALB/c male mice were purchased from
Shanghai Laboratory Animal Centre (Chinese Academy
of Sciences, Shanghai, China). The HCC model of mice
was performed according to a previous report [19].
Briefly, 200 μL (0.5 × 107 cells) of H22 cells suspension
was injected into the abdominal cavity of Kunming
mouse. Ten days later, mice were randomly and equally
divided into several groups (ten mice per group). To
investigate the anti-tumor effect of GLPS, mice were
divided into 5 groups: injection of PBS, 10 mg/kg GLPS,
50 mg/kg GLPS, 100 mg/kg GLPS and 200 mg/kg GLPS.
To observe the role of miR-125b in anti-tumor of GLPS,
mice were also divided into 4 groups: injection of nega-
tive control (5′-CAGUACUUUUGUGUAGUACAA-3′),
miR-125b inhibitor (5′-UCACAAGUUAGGGUCUCAG
GGA-3′), GLPS + negative control, and GLPS +miR-125b
inhibitor. Cholesterol-conjugated miR-125b inhibitor and
negative control oligonucleotide (NC) were purchased
from RiboBio (Guangzhou, China). GLPS in 0.5 ml of PBS
was administered by intraperitoneal injection (i.p.) every
two days for 4 weeks. In GLPS +miR-125b inhibitor
group, miR-125b inhibitor was pretreated for 24 hours
and then injected with GLPS. NC and miR-214 inhibi-
tor (10 nmol) in 0.1 ml of saline buffer was administered
intratumorally every 2 days for 4 weeks. Tumor growth
was assessed two times a week and volume (V) was calcu-
lated using the formula V = 1/2 × length × (width)2.
Isolation of tumor-infiltrating lymphocytes (TILs)
TILs were isolated from the tumors according to previous
report [20]. Briefly, small pieces of solid tumors tissue was
digested with an enzyme cocktail containing 2% fetal
bovine serum, 0.5 mg/ml collagenase A (Roche),
0.2 mg/ml hyaluronidase, type V (Sigma) and 0.02 mg/ml
DNase I (Sigma) per 0.25 g of tumor tissue. The cell
suspensions were filtered through a cell strainer (70 μm,
Becton Dickinson, CA, USA), and then, they were washed
with 2% FBS in RPMI 1640. After lysed red blood cells,
the cell clumps were removed by 40%/70% Percoll gradient
Figure 1 GLPS inhibited hepatoma growth in vivo. The hepatoma-
bearing mice were treated with 0 mg/kg (group 1), 10 mg/kg (group 2),
50 mg/kg (group 3), 100 mg/kg (group 4) and 200 mg/kg (group 5)
GLPS by i.p. injection. (A) Tumor sizes on each mouse were monitored
2 times per week. (B) Tumor weights were measured on day 38
following H22 cells cell inoculation and the images of tumors from
different treatment group were shown. *P < 0.05 and **P < 0.01 indicate
significant differences from group 1.
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lymphocytes were harvested and CD4+ lymphocytes were
isolated by Dynabeads M-450 CD4 according to the manu-
facturer’s instruction. These CD4+ lymphocytes were
further isolated into CD25+ and CD25- lymphocytes by
Dynabeads (Dynal Biotech ASA, Oslo, Norway). CD4 +
CD25+ T cells and/or CD4 + CD25- T cells were added
different concentrations of GLPS, and cultured for
72 h, at 37°C and 5% CO2.
Isolation of lymphocytes from peripheral blood
EDTA-K2 anticoagulated blood samples were collected
from hepatoma-bearing mice. Monocytes were isolatedfrom the peripheral blood by Ficoll-Paque (Pharmacia,
Piscataway, NJ) density centrifugation. The monocytes
were resuspended in RPMI-1640 medium and plated on
a 6-well plate. After 2 hours of incubation at 37°C, the
nonadherent lymphocytes were harvested and subse-
quently cultured.
Isolation of mouse naïve T cells and in vitro T cell
differentiation
Splenic CD4+ naïve T cells from wild type Kunming mice
were isolated using the CD4+ T cell Isolation Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) following the manu-
facturer’s instructions. Isolated naïve T cells were added
different concentrations of GLPS, and cultured in RPMI-
1640 with 10% FCS with 2 ng/ml of mouse TGF-β1, 1500
units/ml of mouse IL-2, and 100 nM of retinoic acid
(iTreg polarizing condition) for 7–10 days.
Flow cytometric analysis
TILs were harvested from the tumors and the lympho-
cytes were isolated from peripheral blood. For intracellu-
lar staining, monoclonal antibodies to surface molecules,
including Anti-CD4-FITC and anti-CD25-PE were used
to stain surface markers. The percentage of CD4 +
CD25- and CD4 + CD25+ T cells was computed using
Cell-Quest software (Becton Dickinson).
Suppression assay
Suppression assays were performed by seeding an equal
number of CD4 +CD25− Tcells and CD4 +CD25+ T cells
(1 × 105/well) into 96-well plates in the presence of PHA
(5 μg/ml) and cultured with or without GLPS for 72 h.
After 72 h, [3H]-thymidine (Amersham Biosciences) was
added (1 μCi/well) for 18 h. Next, [3H]-thymidine incorp-
oration was measured on a β-scintillation counter. Results
were expressed as mean cpm ± SE.
Lymphocyte proliferation assay
The [3H]-thymidine incorporation assay was performed
according to previous report [21]. Briefly, CD4 + CD25−
TILs (1 × 105 /well) were seeded into 96-well plate in the
presence of PHA and cultured with or without GLPS.
After 72 h, each well is pulsed with 1 μCi [3H]-thymi-
dine for 18 h. Cells were harvested, and [3H]-incorpor-
ation measured using a β-scintillation counter. Results
were expressed as the mean cell proliferation in counts
per minute (cpm) ± standard error (SE).
Oligonucleotides and Cell Transfection
Jurkat T cells were seeded in 6-well or 24-well plates
and transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. For the knockdown of miR-125b, anti-miR-
125b or a negative-control anti-miRNA (anti-NC) was
Figure 2 GLPS shifts the intratumoral regulatory T cell (Treg) to effector T cell (Teff) balance. (A) The ratio of intratumoral Tregs to CD4+ cells
was measured by flow cytometric analysis from hepatoma-bearing mice treated with 0 mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg and 200 mg/kg GLPS
by i.p. injection. (B) The ratio of Teff to Treg was calculated. (C) The percentage of CD4+ T cells in tumor was detected by flow cytometric
analysis. (D) The population of Tregs T cells in the peripheral blood of hepatoma-bearing mice was measured with flow cytometric analysis
*P < 0.05 and **P < 0.01 indicate significant differences from hepatoma-bearing mice treated with 0 mg/kg GLPS.
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vested 24 h after the transfection.
Quantitative real-time PCR (Q-PCR) analysis
Mature miRNAs were isolated and purified using Trizol
reagent (Invitrogen, USA), according to manufacturer’s
protocol. The levels of miRNAs (miR-126, miR-155,
miR-146a, miR-224, miR-150 and miR-125b) were quan-
tified by using a TaqMan PCR kit (Applied Biosystems,
Foster City, CA, USA). Commercially available Taqman
primers and probes, including 2 unlabeled PCR primers
and 1 FAMTM dye-labeled TaqMan MGB probe were
used for all the targets. Real-time PCR was performed
using LighteCycler480 II Sequence Detection System
(Roche, Basel, Switzerland). All reactions, including no-
template controls, were performed in triplicate. After
the reaction, the CT values were determined using fixed
threshold settings. In order to calculate the differences
of expression level for each target among samples, the
2-ΔΔCT method for relative quantitation was used. All
data were analyzed using U6 small nuclear RNA as an
internal normalized reference.
The mRNA expression of North1 and FoxP3 was per-
formed using SYBR GREEN PCR Master Mix (Applied
Biosystems). The specific primers were as follows: North1,
5′- CCGGTGAGACCTGCCTGAAT-3′ (forward) and 5′-GCACTTGTACTCCGTC AGCG -3′ (reverse); FoxP3,
5′-ACTGACCAAGGCTTCATCTGTG-3′ (forward) and
5′–GGAACTCTGGGAATGTGCTGT-3′(reverse); GAP
DH, 5′-TGAAGCAGGCA TCTGAGGG-3′ (forward) and
5′-CGAAGGTGGAAGAGTGGGAG-3′ (reverse). All data
were analyzed using GAPDH gene expression as an in-
ternal standard.
Western blot analysis
Jurkat T cells were lysed with ice-cold lysis buffer contain-
ing: 50 mmol/l Tris–HCl, pH 7.4; 1% NP-40; 150 mmol/l
NaCl; 1 mmol/l EDTA; 1 mmol/l phenylmethylsulfonyl
fluoride; and complete proteinase inhibitor mixture
(one tablet per 10 ml; Roche Molecular Biochemicals,
Indianapolis, IN, USA). Protein concentration in the
cell lysate was quantified using the DC protein assay
kit. Following protein content determination, western
blot analysis was performed.
ELISA analysis
Analysis of IL-2 was performed using an ELISA kit accord-
ing to manufacturer’s protocol. Briefly, regulatory T cells
and effector T cells were incubated in a 96-well plate with
different concentrations of GLPS. Production of IL-2 was
normalized to protein concentrations using the DC protein
assay kit (Bio-Rad).
Figure 3 GLPS decreases Treg-mediated suppression on Teff. Tregs and Teffs isolated from the hepatoma-bearing mice. The addition of GLPS
to the cocultures for 72 h and suppression assays were performed (A) and the secretion of IL-2 were determined (B). (C) GLPS treated Teffs from
the hepatoma-bearing mice for 72 h and proliferation assay was performed. (D) IL2 content in the supernatants from the proliferation assay was
determined by ELISA. **P < 0.01, indicate significant differences from Teffs, # P < 0.05 and ## P < 0.01, indicate significant differences from 0 mg/kg
(μg/ml) GLPS.
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Cell viability was determined using MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays. The
cells were seeded in 96-well dishes at 1 × 104 to 2 × 104
cells per well and pretreated with or without GLPS for
24 h. Each well was supplemented with 10 μl MTT (Sigma
Aldrich) and incubated for 4 h at 37°C. The medium was
subsequently removed, and 150 μl DMSO (Sigma Aldrich)
were added to solubilize the MTT formazan. The optical
density was observed at 490 nm.
Statistical analysis
Statistical analysis was performed with statistical analysis
software SPSS 13.0 software. Statistical analyses were
performed using either an analysis of variance (ANOVA)
or Student’s t-test. Data were expressed as mean ± standard
deviation. P < 0.05 was considered to be significant.Results
GLPS inhibited hepatoma growth in vivo
To evaluate the anti-HCC activity of GLPS in vivo, the
hepatoma-bearing mice model was established. After ad-
ministration of GLPS at 10, 50, 100 and 200 mg/kg in
hepatoma-bearing mice by i.p. every two days for 4 weeks,the tumor volume was significantly reduced by 18.3%,
47.08%, 66.92% and 81.9%, respectively. As shown in
Figure 1A, the mean tumor volume on day 38 following
H22 cells cell inoculation, which was 652 ± 25.51 mm3
in control group, was reduced to 118 ± 17.35 mm3 in
the GLPS treatment group (200 mg/kg). Besides, GLPS
treatment significantly decreased the weight of tumors
in a dose-dependent manner (Figure 1B).GLPS shifts the intratumoral regulatory T cell (Treg) to
effector T cell (Teff) balance
To explore the mechanism of GLPS inhibiting tumor
growth in the hepatoma-bearing mice, we investigated
the impact of GLPS on the balance of Treg (distin-
guished as CD4 + CD25+) and Teff (distinguished as
CD4 + CD25-) in the tumor. After injection of GLPS for
4 weeks, the ratio of intratumoral Tregs was dose-
dependently decreased but that of Teffs was increased,
which resulted in an increase of the ratio of Teffs to Tregs
(Figure 2A and B). It should be noted that the percentage
of total CD4+ T cells in tumors remained unchanged
(Figure 2C). Besides, the frequency of Tregs in peripheral
blood from GLPS-injected mice was slightly lower than
that from PBS-injected mice (Figure 2D).
Figure 4 miR-125b was implicated in the effect of GLPS on intratumoral Tregs. (A) The expression of many miRNAs including miR-126, miR-155,
miR-146a, miR-224, miR-150 and miR-125b was measured in Tregs from hepatoma-bearing mice injected with GLPS. **P < 0.01, indicate significant
differences from Tregs isolated from hepatoma-bearing mice injected with 0 mg/kg GLPS. (B) The expression of miR-125b was determined in naïve T
cells under iTreg polarizing condition with various concentrations of the GLPS for 96 h. **P < 0.01, indicate significant differences from 0 μg/ml GLPS
treatment. The mRNA (C) and protein (D) levels of FoxP3 were measured in naïve T cells under iTreg polarizing condition with various concentrations
of the GLPS for 96 h. **P < 0.01, indicate significant differences from 0 μg/ml GLPS treatment. After transfected with miR-125b inhibitor for 24 h, naïve T
cells under iTreg polarizing condition were treated with GLPS (100 μg/ml) for 96 h. Then, the protein levels of FoxP3 (E) and Notch1 (F), and the
mRNA level of Notch1 (G) were determined. **P < 0.01, indicate significant differences from the respective control groups. **P < 0.01, indicate
significant differences from the respective control groups. (H) After transfected with miR-125b inhibitor for 24 h, naïve T cells under iTreg polarizing
condition were treated with GLPS (100 μg/ml) or GLPS (100 μg/ml) + curcumin (30 μmol/L). Then, the FoxP3 protein level was determined.
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It has been confirmed that Tregs have an immunosup-
pressive effect on Teffs [22]. To determine whether GLPS
treatment had an effect on Treg activity, we performed
the suppression assay of Tregs in vitro. Briefly, Tregs and
Teffs isolated from the hepatoma-bearing mice were
co-cultured (1:1) in 96-well plate. The addition of GLPS tothe cocultures for 72 h significantly decreases Tregs-
mediated suppression on Teffs proliferation and increases
IL-2 secretion in dose-dependent manner (Figure 3A and
B). We also performed proliferation assays to evaluate the
direct impact of GLPS on Teffs responses. To our surprise,
GLPS at all tested concentrations did not stimulate Teffs
proliferation without Tregs (Figure 3C). In addition, the
Figure 5 miR-125b plays an important role in anti-tumor effect of GLPS. For down-regulation of miR-125b, miR-125b inhibitor was injected
intratumorally before GLPS administration. Twenty-four hours after the miR-125b inhibitor (10 nmol) injection, hepatoma-bearing mice were
treated with 50 mg/kg GLPS or same volume of PBS by i.p. injection. (A) Tumor sizes on each mouse were monitored 2 times per week.
(B) Tumor weights were measured and the images of tumors from different treatment group were shown. (C) The expression of miR-126b in
Tregs from hepatoma-bearing mice were measured. **P < 0.01 indicated significant differences from negative control injection. # P < 0.05 and
## P < 0.01, indicate significant differences from negative control + GLPS.
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did not affect the release of IL-2 from Teffs alone
(Figure 3D).miR-125b was implicated in the effect of GLPS on
intratumoral Tregs
To further explore the mechanism of GLPS mediating the
alteration of Treg to Teff balance in the HCC tissues, we
measured the expression of many miRNAs including miR-
126, miR-155, miR-146a, miR-224, miR-150 and miR-
125b, which may be involved in Treg cell development
[23]. Among these miRNAs, miR-125b was significantlyincreased in intratumoral Tregs from hepatoma-bearing
mice injected with GLPS (Figure 4A).
To explore the possible role of miR-125b on induction
and function of Tregs, we measured the miR-125b expres-
sion in naïve T cells under iTreg polarizing condition with
various concentrations of the GLPS. After 96 h of treat-
ment, the expression of miR-125b was significantly up-
regulated in a dose-dependent manner (Figure 4B). When
T cells were stimulated with GLPS, the levels of FoxP3 ex-
pression dose-dependently decreased (Figure 4C and D).
The role of miR-125b in the effect of GLPS on Tregs was
further investigated. Through depleting miR-125b in T
cells using a miR-125b inhibitor, the decrease of FoxP3
Li et al. Journal of Translational Medicine  (2015) 13:100 Page 8 of 10expression induced by GLPS was abolished (Figure 4E),
suggesting that the inhibition of Tregs by GLPS might act
through increasing miR-125b expression.
It has been demonstrated that Notch1, a target of miR-
125b, plays an important role in cell growth and apoptosis
of HCC [24,25]. The effect of GLPS on Notch1 expression
in T cells was measured. As shown in Figure 4F, GLPS
treatment significantly down-regulated Notch1 expression,
which was restored by the miR-125b inhibitor (Figure 4G).
In addition, treatment with curcumin, a known Notch1 in-
hibitor, could reverse the effect of miR-125b inhibitor on
FoxP3 expression in T cells exposed to GLPS (Figure 4H).
These data indicate that GLPS could decrease FoxP3 levels
by miR-125b down-regulation of Notch1 expression.
miR-125b plays an important role in anti-tumor effect of
GLPS
To determine whether miR-125b was implicated in the
anti-tumor effect of GLPS, the cholesterol-conjugated
miR-125b inhibitor was administered into the hepatoma-
bearing mice. After intratumoral injection of miR-125b
inhibitor, the tumor volume and weight exhibited a slight
increase. However, miR-125b inhibitor obviously restored
the effect of GLPS on tumor growth (Figure 5A and B). In
addition, the expression of miR-125b was obviously down-
regulated in Tregs from hepatoma-bearing mice injected
with GLPS and miR-125b inhibitor (Figure 5C). These re-
sults suggest that miR-125b plays an important role in the
effect of GLPS on inhibition of HCC tumor growth.
The effect of GLPS on H22 and L-02 cells viability
It has been reported that GLPS induced apoptosis of
HepG2 cells with high dosage [26]. To evaluate the poten-
tial effects of GLPS on the mouse hepatoma H22 cell and
normal hepatic cell line L-02 viability, MTT assays were
preformed. As expected (Figure 6), GLPS did not signifi-
cantly suppress H22 cell viability at 50–100 μg/ml, while
GLPS could inhibit cell viability at higher concentrations
(>100 μg/ml). High dose of GLPS (1000 μg/ml) had no ef-
fect on L-02 cell viability, which indicate normal hepaticFigure 6 The effect of GLPS on H22 and L-02 cells viability. H22 cells (
of GLPS for 48 h, and the cell viability was measured using a MTT assay. **cells showed more resistance to the cytotoxicity effect of
GLPS.
Discussion
Ganoderma lucidum polysaccharides (GLPS), the trad-
itional Chinese medicine, are effective in tumor therapy
with low toxicity [27]. GLPS possess anti-tumor effects on
many cancers through suppression of tumorigenesis, in-
hibition of tumor growth and metastasis, and modulation
of immune cells [28]. In this study, the mechanism of
GLPS on anti-HCC in vivo and in vitro was explored.
First, we demonstrated that GLPS could significantly sup-
presse tumor growth in hepatoma-bearing mice associated
with an increase of the ratio of Teffs to Tregs. GLPS elimi-
nated CD4 +CD25+ Treg suppression of CD4 +CD25-
Teff proliferation with an increase in IL2 secretion.
Second, we showed that inactivation of tumor-infiltrating
Tregs could abolish the antitumor activity of GLPS. Third,
we also showed that miR-125b was implicated in the effect
of GLPS on intratumoral Tregs and played an important
role in anti-tumor effect of GLPS. It should be noted that
GLPS had no effect on the weight of hepatoma-bearing
mice (data not shown) and GLPS was little cytotoxic to
normal hepatic cell line L-02 (Figure 6), which showed the
safety of GLPS to treat HCC.
Regulatory T cells infiltrating the tumor play an im-
portant role in tumor immune evasion and become the
main obstacle for successful HCC immunotherapy [29].
Increased the population of Tregs in both the peripheral
blood and tumor has been shown to correlate with a
poor prognosis in patients with HCC [30]. As a result,
targeting the number and function of Tregs has been the
target for HCC therapies. We provided a direct demon-
stration that GLPS treatment may definitely interfere
with Treg accumulation and function in vivo. After
injection of GLPS for 4 weeks, we established that the
percentage of intratumoral Tregs was decreased in a dose-
dependent manner (Figure 2A). The addition of GLPS to
the cocultures of Tregs and Teffs resulted in a loss of Treg
immunosuppressive properties (Figure 3A). However,A) and L-02 cells (B) were incubated with the indicated concentration
p < 0.01, versus vehicle alone-treated cells.
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proliferation without Tregs. These results demonstrated
that GLPS suppressed liver tumor growth in a direct way
via decreasing Tregs accumulation and activation.
Previous studies showed Notch1 signaling pathway
played an important role in Treg differentiation and sup-
pressor function through regulating FoxP3 expression
[31]. Our data exhibited that GLPS treatment signifi-
cantly down-regulated Notch1 expression in T cells,
which indicated that Notch1 may be involved in GLPS
immunomodulatory function. Further study showed that
treatment with Notch1 inhibitor could reverse the effect
of miR-125b inhibitor on FoxP3 expression in T cells.
This suggested that Notch1 signaling was involved in
GLPS-inhibited FoxP3 expression in T cells. It has been
noted that TGFβ-smad pathway play a key role in the
Treg and Teff balance [32]. We found that GLPS had no
effect on the levels of TGF-β and p-Smad2/3 (data not
shown), which indicated that GLPS downregulated regu-
latory T cells accumulation and function in a TGF-β-
Independent Manner.
It has been demonstrated miR-125b expression was
down-regulated in HCC, which is the prediction of ag-
gressiveness and poor prognosis of HCC [33]. In this
study, we found that miR-125b was implicated in the
effect of GLPS on anti-HCC. First, miR-125b was signifi-
cantly up-regulated in intratumoral Tregs from hepatoma-
bearing mice injected with GLPS. Second, miR-125b
expression displayed an increase in T cells treated with
GLPS. Third, Notch1, a target of miR-125b, was down-
regulated by GLPS. The present study, we have demon-
strated that inhibition of miR-125b expression could
attenuate GLPS-induced decrease of Notch1 level. Last,
the effect of GLPS on suppression of tumor growth was
reversed by miR-125b inhibitor. All these lines of evidence
strongly suggested that GLPS exerted anti-HCC activity
through up-regulation of miR-125b expression.Conclusion
GLPS effectively suppressed tumor growth in hepatoma-
bearing mice. The decrease of Tregs accumulation and
inactivation associated with GLPS administration was due
to increase of miR-125b expression, which resulted in
inhibition of Notch1 signaling pathway and FoxP3 expres-
sion. Overall, these findings have revealed the molecular
mechanisms of GLPS treatment with HCC.
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